Earnings call transcript: Arcutis Q2 2025 beats EPS and revenue forecasts

Arcutis Biotherapeutics (ARQT) significantly surpassed Q2 2025 expectations, reporting an EPS of -$0.13 and revenue of $81.5 million, marking 164% year-over-year growth for its XERIV franchise. This robust performance, coupled with a gross profit margin of 88.39% and achieving slightly positive cash flow for the quarter, underscores strong operational efficiency and progress towards cash flow breakeven by 2026. While the stock saw only a modest 0.26% after-hours gain, the company continues to expand XERIV's indications and advance its pipeline, though it faces ongoing challenges with Medicare Part D coverage and recently halted development of its ARQ255 program.

Analysis

Arcutis Biotherapeutics (ARQT) reported a strong second quarter for 2025, significantly outperforming market expectations. The company posted revenue of $81.5 million, a 164% year-over-year increase, which surpassed forecasts by 11.26%. This top-line growth was driven by robust prescription volume for its XERIV franchise, which saw a 13% quarter-over-quarter increase in scripts. Earnings per share (EPS) of -$0.13 also beat the consensus estimate of -$0.17. Operationally, Arcutis is demonstrating increasing efficiency, highlighted by a high gross profit margin of 88.39% and progress toward its goal of achieving cash flow breakeven in 2026; the company even reported a slightly positive operating cash flow of $325,000 for the quarter, though this was partly attributed to working capital timing. The company's growth strategy centers on expanding XERIV's label, drawing comparisons to the successful life cycle management of Humira and Dupixent. Near-term catalysts include the recent FDA approval for scalp psoriasis and an upcoming PDUFA date in October for pediatric atopic dermatitis. However, significant headwinds persist, most notably the challenges in securing Medicare Part D coverage due to financial disruptions for payers from the Inflation Reduction Act (IRA). Management also guided for moderated sequential growth in Q3 due to seasonality and announced the discontinuation of its ARQ255 program for alopecia areata, framing it as a disciplined capital allocation decision despite the program's failure to meet efficacy endpoints.

Key Decisions for Investors

• Investors should weigh the company's strong fundamental performance and 164% year-over-year revenue growth against the muted 0.26% after-hours stock reaction, which may suggest the market is focused more on near-term headwinds than on operational execution.
• It is critical to monitor for any progress in securing Medicare Part D coverage, as the ongoing challenges related to the IRA implementation represent a significant impediment to accessing roughly half of the addressable government-pay market.
• Key catalysts to watch are the October PDUFA date for XERIV in pediatric atopic dermatitis and future updates on the Phase 2 studies in vitiligo and hidradenitis suppurativa, which will be important validators of the long-term life cycle management thesis.
• Consider the company's high beta of 1.85, indicating above-market volatility, and management's guidance for a seasonal slowdown in Q3 growth when assessing position sizing and entry points.
• The discontinuation of the ARQ255 program, while a pipeline setback, reflects a disciplined approach to capital; future business development and R&D investment decisions will be a key test of management's ability to create value beyond the core XERIV franchise.